An update on the French SCLERADEC I and II clinical trials using Cytori
Therapeutics' (Nasdaq: CYTX) Cell Therapy will be presented tomorrow at
the 104th Annual Meeting of the Japan Society of Aesthetic Surgery. Shares of the biotechnology company soared 88 cents to close at $3.33.
Data to be presented on Cytori Cell Therapy
May 17, 2016 at 17:14 PM EDT
